Clinical Trial Update: Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating letrozole (Femara) versus placebo for ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• FEMARA (letrozole)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: WITHDRAWN